Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
Authors:
- Min-Gui ZhangMZMin-Gui Zhang
- Hua-Xiang XuHXHua-Xiang Xu
- Wen-Quan WangWWWen-Quan Wang
- Liang LiuLLLiang Liu
- Xian-Jun YuXYXian-Jun Yu
Open Access
- 1 May 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (19) , e751-10
Abstract
Serum carbohydrate antigen 19-9 (CA19-9) is widely used to predict the prognosis for pancreatic ductal adenocarcinoma (PDAC). However, hyperbilirubinemia and the CA19-9 nonsecretor phenotype restrict the usage of serum CA19-9 alone. The goal of this study was to confirm the prognostic role of preoperative serum CA125 in PDAC, especially in patients with jaundice. A total of 211 patients with resected PDAC were eligible for this retrospective study, and were classified into 2 groups based on serum bilirubin levels. The prognostic significance of all clinicopathologic factors was evaluated by univariate and multivariate analyses, and the performance of each factor in predicting overall survival (OS) and recurrence-free survival (RFS) was compared. High preoperative CA125, high TNM stage, and lymph node metastasis were independent risk predictors for OS and RFS in all patients and the 2 subgroups, but high CA19-9 was only significant when considering all patients and those with nonelevated bilirubin. Using time-dependent receiver-operating characteristic analysis, better predictive performance for OS and RFS was observed for serum CA19-9 as compared to serum CA125 in these patients. High serum CA125 can independently predict poor prognosis. Importantly, in PDAC patients with hyperbilirubinemia, preoperative serum CA125 can predict the prognosis, whereas CA19-9 cannot. Preoperative CA19-9 had better predictive performance for survival than CA125, and the performance of CA19-9 did not decline between all patients and those with nonelevated bilirubin, but was significantly affected by hyperbilirubinemia.Keywords
This publication has 30 references indexed in Scilit:
- CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology, 2014
- Development of serum parameters panels for the early detection of pancreatic cancerInternational Journal of Cancer, 2013
- Intensity of Follow-up after Pancreatic Cancer ResectionAnnals of Surgical Oncology, 2013
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- Pancreatic cancerThe Lancet, 2011
- Pancreatic AdenocarcinomaJournal of the National Comprehensive Cancer Network, 2010
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant ChemoradiationAnnals of Surgical Oncology, 2010
- Cancer Antigens 19-9 and 125 in the Differential Diagnosis of Pancreatic Mass LesionsArchives of Surgery, 2006
- Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2006
- Utility of Tumor Markers in Determining Resectability of Pancreatic CancerArchives of Surgery, 2003